Skip to main content

Shanghai Allist Pharmaceuticals

Shanghai Allist Pharmaceuticals Co Ltd is a Chinese biopharmaceutical enterprise focused on discovering, developing, and commercializing targeted oncology therapeutics for lung cancer. The company commercializes furmonertinib (Iressa-class third-generation EGFR inhibitor) for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Principal revenue is generated from direct product sales of furmonertinib prescription tablets directly to medical distributors, hospital networks, and retail pharmacies across China. Core end markets encompass thoracic oncology clinics, clinical hospital networks, and lung cancer prescription patients in Mainland China. Shanghai Allist Pharmaceuticals holds a market-leading position in China's domestic targeted lung cancer therapy sector. The company is headquartered in Shanghai, China, and its common shares trade on the STAR Market of the Shanghai Stock Exchange.

4 of the funds FundTelligence covers report a position in Shanghai Allist Pharmaceuticals.

Legal name
Shanghai Allist Pharmaceuticals Co Ltd
Sector
Health Care
Country
China
Funds holding it
4

Funds holding Shanghai Allist Pharmaceuticals

Loading...